Diazoxide affects mitochondrial bioenergetics by the opening of mKATP channel on submicromolar scale

二氮嗪通过亚微摩尔浓度下mKATP通道的开放影响线粒体生物能量学。

阅读:1

Abstract

BACKGROUND: Cytoprotection afforded by mitochondrial ATP-sensitive K(+)-channel (mK(ATP)-channel) opener diazoxide (DZ) largely depends on the activation of potassium cycle with eventual modulation of mitochondrial functions and ROS production. However, generally these effects were studied in the presence of Mg∙ATP known to block K(+) transport. Thus, the purpose of our work was the estimation of DZ effects on K(+) transport, K(+) cycle and ROS production in rat liver mitochondria in the absence of Mg∙ATP. RESULTS: Without Mg·ATP, full activation of native mK(ATP)-channel, accompanied by the increase in ATP-insensitive K(+) uptake, activation of K(+)-cycle and respiratory uncoupling, was reached at ≤0.5 μM of DZ,. Higher diazoxide concentrations augmented ATP-insensitive K(+) uptake, but not mK(ATP)-channel activity. mK(ATP)-channel was blocked by Mg·ATP, reactivated by DZ, and repeatedly blocked by mK(ATP)-channel blockers glibenclamide and 5-hydroxydecanoate, whereas ATP-insensitive potassium transport was blocked by Mg(2+) and was not restored by DZ. High sensitivity of potassium transport to DZ in native mitochondria resulted in suppression of mitochondrial ROS production caused by the activation of K(+)-cycle on sub-micromolar scale. Based on the oxygen consumption study, the share of mK(ATP)-channel in respiratory uncoupling by DZ was found. CONCLUSIONS: The study of mK(ATP)-channel activation by diazoxide in the absence of MgATP discloses novel, not described earlier, aspects of mK(ATP)-channel interaction with this drug. High sensitivity of mK(ATP)-channel to DZ results in the modulation of mitochondrial functions and ROS production by DZ on sub-micromolar concentration scale. Our experiments led us to the hypothesis that under the conditions marked by ATP deficiency affinity of mK(ATP)-channel to DZ can increase, which might contribute to the high effectiveness of this drug in cardio- and neuroprotection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。